Safety report of Siddha polyherbal formulation Kabasura Kudineer.

A prospective Nonrandomized open label-controlled study to report the safety aspects of Siddha Polyherbal decoction formulation Kabasura Kudineer on a 28-day trial among participants volunteered from CISF contingent. - SIDDAR

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/05/042510

Enrollment

280

Registered

2022-05-12

Start date

Unknown

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Kabasura Kudineer: Kabasura Kudineer (KSK) 60 ml Before or after food, twice a day 28 days 1 month from the drug usage Control Intervention1: NA: NA

Eligibility

Inclusion criteria

Inclusion criteria: 1. Any subjects willing to participate in the study (age 18 -60 yrs) from the contingent, CISF

Exclusion criteria

Exclusion criteria: 1. Covid positive cases 2. Subjects under immunotherapies or steroids or any other antiviral drugs 3. Subjects who are unsuitable as per the logical derivations of the investigators 4. Subjects are unwilling to enroll/participate or continue the drug period.

Design outcomes

Primary

Measure	Time frame
To document any range of adverse findings related to the intervention (ADR reporting) of KSK on long term usage among the calculated sample size.Timepoint: 4 weeks	—

Secondary

Measure	Time frame
1. To document the improvement in wellness or other clinical associations particular to the subjectTimepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDr P Sathiyarajeswaran

Siddha Central Research Institute

siddha2k6@gmail.com9443579540

Outcome results